CollaGenex (CGPI) FDA PENDING Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CollaGenex (CGPI) FDA PENDING

CGPI 0.0001000

0.0%

Jul 21 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: thomas larkin who wrote (27)	4/18/1998 9:01:00 PM
From: Tom D	Read Replies (1) of 142

Resistance is not an issue.... because the amount of antiobiotic given is insufficient to kill vulnerable bacteria and select out the resistant organisms. With this dose range, all susceptible bacteria presumably are unaffected. But the small doses are capable of inhibiting the metalloproteinase enzymes which medicate periodontal disease. If I have failed to clarify this, please respond. Best Regards, Tom D

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next